ArticleThe Journal of clinical investigation2026
Nephrin autoimmunity: signal, noise, and a path to clarity.
Article in The Journal of clinical investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Advances in antigen discovery and autoantibody profiling have reshaped the classification of autoimmune kidney diseases, moving beyond purely histologic definitions. The identification of podocyte-targeting autoantibodies has transformed the understanding of nephrotic syndrome, prompting renewed interest in autoimmune mechanisms underlying podocytopathies. Recent reports of nephrin autoantibodies in minimal change disease, the most common cause of nephrotic syndrome in children, suggested a potential antigen-defined subset, but findings have been inconsistent. In this issue of the JCI, Pecoraro and colleagues advance the field by systematically interrogating anti-nephrin antibodies across a diverse nephrotic syndrome cohort using human-based and orthogonal approaches. Their results highlight critical limitations in assay specificity and cohort heterogeneity while raising the question of the clinical utility of anti-nephrin antibodies in the care of patients with minimal change disease. More broadly, this study underscores the need for collaboration to establish standardized assays and rigorously phenotyped cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.